You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Cell-penetrating antimicrobial therapeutics for treatment of complicated skin and soft tissue infections

    SBC: TSRL, INC.            Topic: NIAID

    Abstract In the United Statesskin and soft tissue infectionsSSTIsare one of the most common indications for antibiotic treatmentrepresentingof hospital admissions andmillion doctor visits a yearSSTIs range from selflimiting furuncles and cellulitis to life threatening sepsis and tissue necrosisRecent studies suggest more thanof all SSTIs were caused by staphylococcal or streptococcal speciesin par ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. A Novel Probiotic Platform to Treat Necrotizing Enterocolitis

    SBC: MONON BIOVENTURES LLC            Topic: 300

    PROJECT SUMMARY Probiotics hold enormous potential for promoting human health and treating disease One major hurdle to many probiotic products is their lack of persistence in the gut Monon Bioventures MBV and their research partners at the Research Institute at Nationwide Childrenandapos s Hospital RINCH are developing a novel enhanced tunable technology called ProNextTM that allows for a ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Cerenkov Multi-Spectral Imaging (CMSI) for Adaptation and Real-Time Imaging in Radiotherapy

    SBC: ENDECTRA LLC            Topic: 102

    PROJECT SUMMARY Understanding of tumor molecular characteristics during a course of radiotherapy (RT) treatment is crucial to assess the efficacy of the treatment and adapt radiation dosage to optimize outcomes. Unfortunately, this cannot be routinely achieved by current diagnostic nuclear imaging modalities due to complex logistics and prohibitive costs. Alternatively, Cerenkov Emission (CE) is a ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Photo-mediated ultrasound therapy for treatment of cutaneous vascular malformations

    SBC: PHOTOSONOX LLC            Topic: NIBIB

    ABSTRACT: Cutaneous vascular malformations (CVM), such as port wine stain (PWS) which occurs in 0.3–0.5% of newborns, are often a cause of great concern to patients for both medical and cosmetic reasons. Laser irradiation with flashlamp-pumped pulsed dye lasers, i.e. photothermolysis therapy (PTT), is currently the gold standard treatment for PWS. Most patients with PWS, however, fail to clear c ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. RememberStuff: a dyadic-focused technology to support persons with Alzheimer's disease in the community

    SBC: EPERTURE LLC            Topic: NIA

    Project Abstract An estimated 5.7 million Americans have Alzheimer’s disease or a related dementia (ADRD) and one in ten people age 65 or older show symptoms of Alzheimer’s disease. As ADRD progresses so does the level of dependency on others. As the disease progresses, higher levels of dependence in people with Alzheimer’s disease are associated with significantly increased burden and costs ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Developing high throughput measurement of thiopurine in DNA by mass spectrometry

    SBC: TYMORA ANALYTICAL OPERATIONS LLC            Topic: 400

    PROJECT SUMMARY Thiopurines such as mercaptopurine are S-substituted antimetabolites used as functional analogs to natural nucleobase precursors. They are highly effective against hematologic malignancies (leukemia and lymphoma) and autoimmune diseases (inflammatory bowel diseases [IBD]), with an estimated patient population andgt;350,000 in the US. However, the cytotoxicity of thiopurines depends ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Fc folate Conjugate for the Treatment of Triple Negative Breast Cancer

    SBC: NeuLink Inc.            Topic: 100

    Abstract According to the American Cancer Society in women in the U S will develop breast cancer at some point in their life and of these women will have triple negative breast cancer TNBC an aggressive subtype of breast cancer that lacks the three receptors ER PR HER that current drug treatment targets tamoxifen Herceptin Because of its aggressive nature and lack of effec ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Optimized AAV Serotype Vectors for Human Gene Therapy

    SBC: Medosome Biotec, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Adeno associated virus AAV is a non pathogenic human parvovirus and recombinant AAV vectors have gained significant attention owing to their safety and in some cases clinical efficacy in a number of Phase I II clinical trials However relatively large vector doses are needed to achieve clinical efficacy and such high doses can lead to host immune respon ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Development of peptide inhibitors for neuroinflammation and neurodegeneration

    SBC: PROVAIDYA            Topic: NIA

    DESCRIPTION provided by applicant The prevalence of Alzheimerandapos s disease AD is poised to increase exponentially with the growing aging population worldwide In the United States total annual costs of AD care are projected to increase from $ billion in to over $ trillion in Paucity of disease modifying therapies capable of slowing the disease progression is an acute unmet ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. A Novel STAT3 Inhibitor Targeting its DNA-Binding Site for Drug Development

    SBC: QRKANSWER LLC            Topic: NCI

    DESCRIPTION provided by applicant Cancer is a major public health problem and a leading cause of mortality claiming more than half million lives every year in the US While major progresses have been made in developing targeted anticancer therapeutics many cancers such as lung cancers have no effective treatments Unfortunately many ideal oncogenic targets including transcription factors for ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government